Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single-Center, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CHK-336 in Healthy Volunteers

Next Previous
Trial Profile

A Phase 1, Single-Center, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CHK-336 in Healthy Volunteers

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CHK-336 (Primary)
  • Indications Primary hyperoxaluria
  • Focus Adverse reactions; First in man
  • Sponsors Chinook Therapeutics

Most Recent Events

  • 01 Nov 2023 Status changed from suspended to discontinued.
  • 17 Jun 2023 According to a Chinook Therapeutics media release, company continue to investigate the SAE observed in the 125 mg MAD cohort and consider next steps, CHK-336 program will remain paused.
  • 17 Jun 2023 According to a Chinook Therapeutics media release, data from this trial presented today in a free communication presentation on CHK-336 at the 60th ERA Congress being held virtually and live in Milan, Italy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top